RESMED INC shareholders Q3 2023

RESMED INC's ticker is RMD and the CUSIP is 761152107. A total of 650 filers reported holding RESMED INC in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.

RESMED INC shareholders Q3 2023
Name	Shares	Value	Weighting ↓
Fund Management at Engine No. 1 LLC	2,101	$310,675	0.05%
Chevy Chase Trust Holdings, LLC	82,627	$12,218,055	0.05%
METROPOLITAN LIFE INSURANCE CO/NY	6,079	$898,902	0.05%
CANADA PENSION PLAN INVESTMENT BOARD	215,697	$31,895,115	0.05%
SECURIAN ASSET MANAGEMENT, INC	10,534	$1,557,663	0.05%
Handelsbanken Fonder AB	57,373	$8,484	0.05%
TEACHER RETIREMENT SYSTEM OF TEXAS	46,422	$6,864	0.05%
Covestor Ltd	409	$61	0.05%
State of New Jersey Common Pension Fund D	83,598	$12,361,636	0.04%
Edgestream Partners, L.P.	3,826	$565,751	0.04%
Dai-ichi Life Insurance Company, Ltd	13,934	$2,060,421	0.04%
YOUSIF CAPITAL MANAGEMENT, LLC	23,371	$3,455,870	0.04%
TEXAS PERMANENT SCHOOL FUND CORP	30,361	$4,489,481	0.04%
Cohen Klingenstein LLC	6,346	$938,383	0.04%
Mitsubishi UFJ Trust & Banking Corp	116,101	$17,167,856	0.04%
NORTHERN TRUST CORP	1,491,269	$220,513,947	0.04%
Alta Advisers Ltd	500	$73,935	0.04%
Sumitomo Mitsui Trust Holdings, Inc.	352,766	$52,163,508	0.04%
AMERICAN INTERNATIONAL GROUP, INC.	45,138	$6,674,556	0.04%
FIL Ltd	242,865	$35,912,447	0.04%

About RESMED INC

ResMed Inc. is a global leader in the development, manufacturing, and distribution of medical equipment for the treatment of sleep apnea and other respiratory disorders. The company has been in operation for over 30 years and has a strong reputation for innovation and quality.

ResMed's products include continuous positive airway pressure (CPAP) machines, masks, and accessories. These products are designed to help patients with sleep apnea breathe more easily and get a better night's sleep. The company's products are sold in over 120 countries worldwide, and ResMed has a strong presence in both the home healthcare and hospital markets.

One of the key strengths of ResMed is its commitment to research and development. The company invests heavily in R&D, and has a team of over 1,000 engineers and scientists working to develop new products and improve existing ones. This focus on innovation has helped ResMed to maintain its position as a market leader in the sleep apnea treatment market.

In addition to its strong product portfolio, ResMed has a solid financial position. The company has consistently delivered strong financial results, with revenue and earnings growth outpacing the industry average. ResMed's strong financial position has allowed it to invest in new product development and expand its global footprint.

Overall, ResMed is a well-established and respected company in the medical equipment industry. With a strong focus on innovation and a solid financial position, the company is well-positioned for continued growth and success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists RESMED INC's shareholders in Q3 2023. To view RESMED INC's shareholder history, click here.